Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck & Co., Inc. reported past fourth-quarter 2025 results with sales of US$16.40 billion and net income of US$2.96 billion, ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Merck (MRK) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2.03 per share.

PayPal ( PYPL) stock tumbled 16.9% before the opening bell after the fintech issued disappointing guidance, delivered ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...